» Articles » PMID: 15337559

Radiosurgery for Treatment of Brain Metastases: Estimation of Patient Eligibility Using Three Stratification Systems

Overview
Specialties Oncology
Radiology
Date 2004 Sep 1
PMID 15337559
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To compare three patient stratification systems predicting survival: recursive partitioning analysis (RPA), score index for radiosurgery in brain metastases (SIR), and a proposed basic score for brain metastases (BS-BM).

Methods And Materials: We analyzed the outcome of 110 patients treated with Leksell Gamma Knife radiosurgery between December 1999 and January 2003. The BS-BM was calculated by evaluating three main prognostic factors: Karnofsky performance status, primary tumor control, and presence of extracranial metastases.

Results: The median survival was 27.6 months for RPA Class I, 10.7 months for RPA Class II, and 2.8 months for RPA Class III (p <0.0001). Using the SIR, the median survival was 27.7, 10.8, 4.6, and 2.4 months for a score of 8-10, 5-7, 4, and 0-3, respectively (p <0.0001). The median survival was undefined in patients with a BS-BM of 3 (55% at 32 months) and was 13.1 months for a BS-BM of 2, 3.3 months for a BS-BM of 1, and 1.9 months for a BS-BM of 0 (p <0.0001). The backward elimination model in multivariate Cox analysis identified SIR and BS-BM as the only two variables significantly associated with survival (p = 0.031 and p = 0.043, respectively).

Conclusion: SIR and BS-BM were the most accurate for estimating survival. They were specific enough to identify patients with short survival (SIR 0-3 and BS-BM 0). Because of it simplicity, BS-BM is easier to use.

Citing Articles

Machine Learning-based Prognostic Model for Brain Metastasis Patients: Insights from Blood Test Analysis.

Li R, Liu Z, Wei Z, Huang R, Pei Y, Yang J J Cancer. 2025; 16(2):689-699.

PMID: 39744477 PMC: 11685702. DOI: 10.7150/jca.103847.


Validity test of small cell lung cancer (SCLC) graded prognostic assessment and proposal of a new index for patients with brain metastases from SCLC.

Yamamoto M, Serizawa T, Sato Y, Higuchi Y, Kikuchi Y, Sato S Clin Transl Radiat Oncol. 2024; 48:100820.

PMID: 39156739 PMC: 11328021. DOI: 10.1016/j.ctro.2024.100820.


Survival after Stereotactic Radiosurgery in the Era of Targeted Therapy: Number of Metastases No Longer Matters.

de Boisanger J, Brewer M, Fittall M, Tran A, Thomas K, Dreibe S Curr Oncol. 2024; 31(6):2994-3005.

PMID: 38920712 PMC: 11202506. DOI: 10.3390/curroncol31060228.


Prognosis versus Actual Outcomes in Stereotactic Radiosurgery of Brain Metastases: Reliability of Common Prognostic Parameters and Indices.

Mangesius J, Seppi T, Arnold C, Mangesius S, Kerschbaumer J, Demetz M Curr Oncol. 2024; 31(4):1739-1751.

PMID: 38668035 PMC: 11049204. DOI: 10.3390/curroncol31040132.


Stereotactic Radiosurgery and Stereotactic Fractionated Radiotherapy in the Management of Brain Metastases.

Benkhaled S, Schiappacasse L, Awde A, Kinj R Cancers (Basel). 2024; 16(6).

PMID: 38539428 PMC: 10968598. DOI: 10.3390/cancers16061093.